Jiangsu Nhwa Pharmaceutical Co Ltd (002262) - Total Liabilities
Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has total liabilities worth CN¥1.30 Billion CNY (≈ $189.81 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jiangsu Nhwa Pharmaceutical Co Ltd - Total Liabilities Trend (2005–2025)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Jiangsu Nhwa Pharmaceutical Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Nhwa Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Centuri Holdings, Inc.
NYSE:CTRI
|
USA | $1.45 Billion |
|
Hercules Capital Inc
NYSE:HTGC
|
USA | $2.22 Billion |
|
Colt CZ Group SE
PR:CZG
|
Czech Republic | Kč25.98 Billion |
|
Megacable Holdings S. A. B. de C. V
MX:MEGACPO
|
Mexico | MX$37.96 Billion |
|
China Suntien Green Energy Corp Ltd
SHG:600956
|
China | CN¥58.87 Billion |
|
Enea S.A.
WAR:ENA
|
Poland | zł18.90 Billion |
|
Steven Madden Ltd
NASDAQ:SHOO
|
USA | $1.01 Billion |
|
Dynex Capital Inc
NYSE:DX
|
USA | $21.62 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Jiangsu Nhwa Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Jiangsu Nhwa Pharmaceutical Co Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Nhwa Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)
The table below shows the annual total liabilities of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.20 Billion ≈ $174.92 Million |
+2.47% |
| 2024-12-31 | CN¥1.17 Billion ≈ $170.69 Million |
+27.06% |
| 2023-12-31 | CN¥918.09 Million ≈ $134.35 Million |
+2.30% |
| 2022-12-31 | CN¥897.43 Million ≈ $131.32 Million |
+13.10% |
| 2021-12-31 | CN¥793.45 Million ≈ $116.11 Million |
+12.28% |
| 2020-12-31 | CN¥706.67 Million ≈ $103.41 Million |
+18.43% |
| 2019-12-31 | CN¥596.68 Million ≈ $87.31 Million |
-44.48% |
| 2018-12-31 | CN¥1.07 Billion ≈ $157.26 Million |
+27.90% |
| 2017-12-31 | CN¥840.24 Million ≈ $122.95 Million |
-1.26% |
| 2016-12-31 | CN¥850.97 Million ≈ $124.52 Million |
+17.60% |
| 2015-12-31 | CN¥723.60 Million ≈ $105.89 Million |
-16.21% |
| 2014-12-31 | CN¥863.61 Million ≈ $126.37 Million |
+18.28% |
| 2013-12-31 | CN¥730.13 Million ≈ $106.84 Million |
+10.22% |
| 2012-12-31 | CN¥662.41 Million ≈ $96.93 Million |
+23.22% |
| 2011-12-31 | CN¥537.59 Million ≈ $78.67 Million |
+9.32% |
| 2010-12-31 | CN¥491.74 Million ≈ $71.96 Million |
+27.83% |
| 2009-12-31 | CN¥384.68 Million ≈ $56.29 Million |
-0.25% |
| 2008-12-31 | CN¥385.66 Million ≈ $56.43 Million |
-13.22% |
| 2007-12-31 | CN¥444.39 Million ≈ $65.03 Million |
+16.44% |
| 2006-12-31 | CN¥381.63 Million ≈ $55.85 Million |
+6.86% |
| 2005-12-31 | CN¥357.12 Million ≈ $52.26 Million |
-- |
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin… Read more